Trials / Completed
CompletedNCT00812175
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,371 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Systemic oral therapy according to product information |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2008-12-22
- Last updated
- 2016-10-17
Locations
75 sites across 39 countries: United States, Canada, China, Colombia, Croatia, Czechia, Finland, France, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Kazakhstan, Libya, Malaysia, Mexico, Norway, Pakistan, Philippines, Portugal, Qatar, Romania, Russia, Singapore, Slovakia, South Korea, Spain, Sweden, Syria, Thailand, Ukraine, United Arab Emirates, Uruguay, Venezuela, Vietnam
Source: ClinicalTrials.gov record NCT00812175. Inclusion in this directory is not an endorsement.